Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carmoterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 20/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 18/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carmoterol SCHEMBL10494358 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL617717 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL13619222 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL5990417 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL11912044 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL10494565 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL594076 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL10494473 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL29355060 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL364838 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739294-A1 | AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE FOR THE TREATMENT OF ASTHMA | Norton (Waterford) Limited (IE) | 2026-05-13 | — | — | EP | claimed |
| EP-4739295-A1 | AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE FOR THE TREATMENT OF ASTHMA | Norton (Waterford) Limited (IE) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260069601-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION FOR PREVENTING OR TREATING RESPIRATORY DISEASE | LEXENPHARM SUZHOU LTD (CN) | 2026-03-12 | — | — | US | claimed |
| EP-4678170-A1 | A FIXED-DOSE DRY POWDER INHALATION FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE FOR THE TREATMENT OF ASTHMA | Norton (Waterford) Limited (IE) | 2026-01-14 | — | — | EP | claimed |
| EP-4642463-A1 | PHARMACEUTICAL COMPOSITIONS OF GREEN PROPELLANT | Cipla Limited (IN) | 2025-11-05 | — | — | EP | claimed |
| US-20250312274-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-10-09 | — | — | US | claimed |
| US-20250302742-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-10-02 | — | — | US | claimed |
| EP-4585215-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION FOR PREVENTING OR TREATING RESPIRATORY DISEASE | Lexenpharm (Suzhou) Limited (CN) | 2025-07-16 | — | — | EP | claimed |
| US-12329759-B2 | Methods and compositions relating to lung function | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-06-17 | — | — | US | claimed |
| US-7018618-B2 | An aerosol solution composition for use in an aerosol inhaler comprises an active material, a propellant containing a hydrofluoroalkane, a cosolvent and optionally a low volatility component to increase the mass median aerodynamic diameter of | CHIESI FARMACEUTICI S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| EP-1595531-A1 | Stable pharmaceutical solution formulations for pressurized metered dose inhalers | CHIESI FARMACEUTICI S.p.A. (IT) | 2005-11-16 | — | — | EP | claimed |
| US-20050220718-A1 | Stable pharmaceutical solution formulations for pressurized metered dose inhalers | CHIESI FARMACEUTICI S.P.A. (IT) | 2005-10-06 | — | — | US | claimed |
| US-20050154013-A1 | Pressurised metered dose inhalers containing solutions of beta-2 agonists | CHIESI FARMACEUTICI S.P.A. (IT) | 2005-07-14 | — | — | US | claimed |
| EP-1466594-A2 | Stable pharmaceutical solution formulations for pressurised metered dose inhalers | CHIESI FARMACEUTICI S.p.A. (IT) | 2004-10-13 | — | — | EP | claimed |
| EP-1452179-A1 | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid | CHIESI FARMACEUTICI S.p.A. (IT) | 2004-09-01 | — | — | EP | claimed |
| US-RE33024-E | Bronchodilating 8-hydroxy-5-(1R)-1-hydroxy-2-(N-((1R)-2-(p-methoxyphenyl)-1-methylethyl)-amino)ethyl) carbostyril and intermediates thereof | TANABE SEIYAKU CO. LTD. (JP) | 1989-08-15 | — | — | US | claimed |
| EP-0147719-B1 | NOVEL CARBOSTYRIL DERIVATIVE AND PROCESS FOR PREPARING SAME | Tanabe Seiyaku Co., Ltd. (JP) | 1989-07-26 | — | — | EP | claimed |
| US-4579854-A | ADRENERGIC STIMULANTS | TANABE SEIYAKU CO., LTD. (JP) | 1986-04-01 | — | — | US | claimed |
| EP-0147719-A2 | Novel carbostyril derivative and process for preparing same | Tanabe Seiyaku Co., Ltd. (JP) | 1985-07-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069601-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION FOR PREVENTING OR TREATING RESPIRATORY DISEASE | ADRB2, ADRB3, CHRM3 | ADRB2 1/4885ADRB1 8/4885 |
| US-20050220718-A1 | Stable pharmaceutical solution formulations for pressurized metered dose inhalers | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PDE7A, HRH1 | ADRB2 75/4885ADRB1 71/4885 |
| US-20050154013-A1 | Pressurised metered dose inhalers containing solutions of beta-2 agonists | ADRB2, ADRA2A, ADRA1D | ADRB2 1/4885ADRB1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.